Stoke's Zorevunersen Shows Durable Seizure and Cognitive Gains in 4-Year Dravet Data
STOK sits 60% above its 52-week low of $18.8.
Summary
Stoke and Biogen presented long-term data from Phase 1/2a and open-label extension studies of zorevunersen in Dravet syndrome at the European Epilepsy Congress. The 4-year results show 77% of patients remaining on treatment, with statistically significant improvements in cognition and behavior at every yearly timepoint. A new sub-analysis found substantial reductions in the most severe seizure types (GTC and focal-to-BTC), which are the leading risk factor for SUDEP. Quality of life also improved through 28 months. Safety remains generally well tolerated, though elevated CSF protein occurred in 94% of patients without serious clinical manifestations. These data strengthen the disease-modifying profile ahead of the Phase 3 EMPEROR readout expected in Q3 2027. The news is most material for Stoke, which retains U.S. rights; Biogen holds ex-U.S. commercialization rights.
At the time of this announcement, STOK was trading at $29.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.80 to $40.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.